Efficacy, Safety, and Tolerability of Aliskiren Monotherapy Administered With a Light Meal in Elderly Hypertensive Patients: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Evaluation Study

This randomized, double-blind, placebo-controlled study assessed the efficacy, safety, and tolerability of aliskiren 75, 150, and 300 mg to clarify the dose-response relationship and characterize the optimum aliskiren dose when given with a light meal to elderly hypertensive patients. After washout,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2012-12, Vol.52 (12), p.1901-1911
Main Authors: Villa, Giuseppe, Breton, Stephanie Le, Ibram, Ghionul, Keefe, Deborah L.
Format: Article
Language:English
Subjects:
Aged
aliskiren
Amides - administration & dosage
Antihypertensive Agents - administration & dosage
Blood pressure
Blood Pressure - drug effects
Dose-Response Relationship, Drug
Double-Blind Method
elderly
Female
food
Fumarates - administration & dosage
Humans
hypertension
Hypertension - drug therapy
Hypertension - physiopathology
Male
Meals
renin-angiotensin-aldosterone system
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This randomized, double-blind, placebo-controlled study assessed the efficacy, safety, and tolerability of aliskiren 75, 150, and 300 mg to clarify the dose-response relationship and characterize the optimum aliskiren dose when given with a light meal to elderly hypertensive patients. After washout, 754 patients aged ≥65 years with hypertension (mean sitting systolic blood pressure [msSBP] ≥150 and
ISSN:0091-2700
1552-4604
DOI:10.1177/0091270011426432